RT Journal Article
SR Electronic
T1 The Lescol Intervention Prevention Study (Lips)
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 561
OP 566
VO 70
IS 6
A1 Adrian W. Messerli
A1 Herbert D. Aronow
A1 Dennis L. Sprecher
YR 2003
UL http://www.ccjm.org/content/70/6/561.abstract
AB The Lescol Intervention Prevention Study (LIPS) was the first randomized trial to show a significant reduction in the risk of cardiac events in patients started on fluvastatin immediately after a successful percutaneous coronary intervention. The benefit was independent of baseline cholesterol levels. The results suggest that all patients should be discharged on lipid-lowering therapy after a percutaneous coronary intervention. Currently, this is seldom done.